New Age Alpha Advisors LLC Acquires New Shares in Ascendis Pharma A/S (NASDAQ:ASND)

New Age Alpha Advisors LLC purchased a new position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 3,680 shares of the biotechnology company's stock, valued at approximately $507,000.

Several other institutional investors have also added to or reduced their stakes in the business. Groupama Asset Managment bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter valued at about $60,000. Janus Henderson Group PLC increased its stake in Ascendis Pharma A/S by 6.8% in the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company's stock worth $625,075,000 after purchasing an additional 267,881 shares during the period. Frazier Life Sciences Management L.P. bought a new stake in Ascendis Pharma A/S in the third quarter valued at approximately $19,908,000. Zimmer Partners LP bought a new stake in Ascendis Pharma A/S in the third quarter valued at approximately $11,646,000. Finally, American Century Companies Inc. grew its holdings in shares of Ascendis Pharma A/S by 17.5% in the fourth quarter. American Century Companies Inc. now owns 407,294 shares of the biotechnology company's stock worth $56,072,000 after purchasing an additional 60,548 shares during the last quarter.

Ascendis Pharma A/S Trading Down 4.9 %

ASND traded down $7.42 during midday trading on Friday, reaching $142.67. The company's stock had a trading volume of 576,851 shares, compared to its average volume of 471,865. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $169.37. The stock's 50-day moving average is $146.39 and its 200-day moving average is $137.93. The firm has a market capitalization of $8.66 billion, a price-to-earnings ratio of -20.09 and a beta of 0.61.

Remove Ads

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($1.32) by $0.64. As a group, equities research analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ASND. Morgan Stanley set a $180.00 price target on shares of Ascendis Pharma A/S in a report on Tuesday, February 18th. JPMorgan Chase & Co. raised their target price on Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 18th. Cantor Fitzgerald boosted their price target on Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a report on Tuesday, February 25th. The Goldman Sachs Group increased their price objective on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Finally, UBS Group initiated coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They set a "buy" rating and a $196.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Ascendis Pharma A/S currently has an average rating of "Moderate Buy" and an average target price of $204.64.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.